Literature DB >> 28209603

Deoxyribonuclease partially ameliorates thioacetamide-induced hepatorenal injury.

Lenka Vokálová1, Lucia Lauková2, Jozef Čonka2, Veronika Melišková2, Veronika Borbélyová2, Janka Bábíčková2, L'ubomíra Tóthová2, Július Hodosy1,2, Barbora Vlková2, Peter Celec3,4,5.   

Abstract

Several recent studies have shown that liver injury is associated with the release of DNA from hepatocytes. This DNA stimulates innate immunity and induces sterile inflammation, exacerbating liver damage. Similar mechanisms have been described for acute renal injury. Deoxyribonuclease degrades cell-free DNA and can potentially prevent some of the induced tissue damage. This study analyzed the effects of thioacetamide-induced hepatorenal injury on plasma DNA in rats. Plasma DNA of both nuclear and mitochondrial origin was higher in thioacetamide-treated animals. Administration of deoxyribonuclease resulted in a mild, nonsignificant decrease in total plasma DNA and plasma DNA of mitochondrial origin but not of nuclear origin. This was accompanied by a decrease in bilirubin, creatinine, and blood urea nitrogen as markers of renal function. In conclusion, the study confirmed the hepatotoxic and nephrotoxic effect of thioacetamide. The associated increase in cell-free DNA seems to be involved in hepatorenal pathogenesis because treatment with deoxyribonuclease resulted in a partial prevention of hepatorenal injury. Further experiments will focus on the effects of long-term treatment with deoxyribonuclease in other clinically more relevant models. Clinical studies should test endogenous deoxyribonuclease activity as a potential risk determinant for kidney or liver failure.NEW & NOTEWORTHY Thioacetamide-induced hepatorenal injury resulted in higher plasma cell-free DNA. Deoxyribonuclease decreased average cell-free DNA of mitochondrial origin but not nuclear origin. Deoxyribonuclease partially prevented hepatorenal injury in rats.
Copyright © 2017 the American Physiological Society.

Entities:  

Keywords:  DNase; circulating nucleic acids; hepatorenal syndrome; liver failure; renal failure

Mesh:

Substances:

Year:  2017        PMID: 28209603     DOI: 10.1152/ajpgi.00446.2016

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  7 in total

1.  Sex Difference in Plasma Deoxyribonuclease Activity in Rats.

Authors:  Ľ Janovičová; B Gromová; D Drobná; B Konečná; E Renczés; V Borbélyová; J Hodosy; P Celec
Journal:  Physiol Res       Date:  2021-10-30       Impact factor: 1.881

2.  Isolation and Quantification of Extracellular DNA from Biofluids.

Authors:  Ľubica Janovičová; Barbora Konečná; Barbora Vlková; Peter Celec
Journal:  Bio Protoc       Date:  2020-08-20

3.  Fagonia indica Repairs Hepatic Damage through Expression Regulation of Toll-Like Receptors in a Liver Injury Model.

Authors:  Fareeha Azam; Nadeem Sheikh; Gibran Ali; Asima Tayyeb
Journal:  J Immunol Res       Date:  2018-07-02       Impact factor: 4.818

Review 4.  Deoxyribonucleases and Their Applications in Biomedicine.

Authors:  Lucia Lauková; Barbora Konečná; Ľubica Janovičová; Barbora Vlková; Peter Celec
Journal:  Biomolecules       Date:  2020-07-11

5.  Plasma DNA and deoxyribonuclease are associated with glucose metabolism in healthy mice.

Authors:  Katarína Kmeťová; Jozef Čonka; Jakub Janko; Júlia Illés; Oľga Uličná; Peter Celec
Journal:  PLoS One       Date:  2022-04-06       Impact factor: 3.240

Review 6.  The Citrullination-Neutrophil Extracellular Trap Axis in Chronic Diseases.

Authors:  Martin Maronek; Roman Gardlik
Journal:  J Innate Immun       Date:  2022-03-09       Impact factor: 7.111

7.  Extracellular DNA concentrations in various aetiologies of acute kidney injury.

Authors:  Alexandra Gaál Kovalčíková; Ľubica Janovičová; Július Hodosy; Janka Bábíčková; Diana Vavrincová-Yaghi; Peter Vavrinec; Peter Boor; Ľudmila Podracká; Katarína Šebeková; Peter Celec; Ľubomíra Tóthová
Journal:  Sci Rep       Date:  2022-10-07       Impact factor: 4.996

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.